Cipher Pharmaceuticals (TSE:CPH) Director Buys 20,000 Shares

Cipher Pharmaceuticals Inc. (TSE:CPH) (NASDAQ:CPHR) Director Craig Mull acquired 20,000 shares of the business’s stock in a transaction dated Friday, September 18th. The stock was acquired at an average price of C$14.16 per share, with a total value of C$283,200.00. Following the completion of the transaction, the director directly owned 1,009,953 shares of the company’s stock, valued at approximately C$14,300,934.48. This represents a 2.02% increase in their ownership of the stock.

Cipher Pharmaceuticals Price Performance

Shares of CPH stock traded up C$0.21 during trading hours on Tuesday, hitting C$14.63. 5,804 shares of the company’s stock were exchanged, compared to its average volume of 30,545. Cipher Pharmaceuticals Inc. has a fifty-two week low of C$12.48 and a fifty-two week high of C$20.56. The firm has a market cap of C$371.82 million, a P/E ratio of 13.06 and a beta of 1.05. The company has a quick ratio of 2.67, a current ratio of 1.59 and a debt-to-equity ratio of 0.27. The firm has a 50 day moving average of C$15.33 and a two-hundred day moving average of C$16.51.

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) last issued its quarterly earnings results on Tuesday, August 11th. The company reported C$0.21 EPS for the quarter. Cipher Pharmaceuticals had a net margin of 58.81% and a return on equity of 22.74%. The company had revenue of C$17.14 million during the quarter. Sell-side analysts forecast that Cipher Pharmaceuticals Inc. will post 1.2907348 EPS for the current year.

About Cipher Pharmaceuticals

Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products, mainly in dermatology. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America.